Mural Oncology plc (NASDAQ:MURA) Shares Sold by BNP Paribas Financial Markets

BNP Paribas Financial Markets trimmed its holdings in shares of Mural Oncology plc (NASDAQ:MURA) by 71.0% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 28,048 shares of the company’s stock after selling 68,686 shares during the period. BNP Paribas Financial Markets’ holdings in Mural Oncology were worth $88,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the stock. Acadian Asset Management LLC acquired a new position in shares of Mural Oncology during the second quarter worth $998,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Mural Oncology during the 2nd quarter worth approximately $84,000. Armistice Capital LLC acquired a new position in shares of Mural Oncology in the 2nd quarter valued at approximately $5,300,000. Primecap Management Co. CA purchased a new position in shares of Mural Oncology during the 2nd quarter valued at approximately $740,000. Finally, Cubist Systematic Strategies LLC acquired a new stake in shares of Mural Oncology during the second quarter worth approximately $98,000. 80.21% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

MURA has been the topic of several recent analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 price target on shares of Mural Oncology in a report on Monday, November 11th. Raymond James assumed coverage on shares of Mural Oncology in a research note on Friday, October 4th. They issued a “strong-buy” rating and a $18.00 target price on the stock.

Insiders Place Their Bets

In related news, CFO Adam D. Cutler sold 7,421 shares of the stock in a transaction dated Thursday, October 31st. The shares were sold at an average price of $3.41, for a total transaction of $25,305.61. Following the sale, the chief financial officer now owns 71,438 shares in the company, valued at $243,603.58. This represents a 9.41 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.06% of the stock is owned by corporate insiders.

Mural Oncology Trading Down 5.9 %

MURA stock opened at $3.19 on Thursday. The firm has a market cap of $54.29 million and a P/E ratio of -0.35. The stock’s 50 day simple moving average is $3.62 and its 200 day simple moving average is $3.39. Mural Oncology plc has a 12-month low of $2.88 and a 12-month high of $6.25.

Mural Oncology Company Profile

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.